XBD173
Sponsors
Novartis Pharmaceuticals, Imperial College London
Conditions
Alzheimer s DiseaseAnxiety DisordersCerebral Small Vessel DiseaseHealthy Volunteers - Male and FemaleHeathly VolunteersMultiple SclerosisNeurodegenerative DisordersPAH
Phase 1
Phase 2
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
CompletedNCT00108836
Start: 2005-03-31End: 2006-05-31Target: 400Updated: 2010-05-20
TSPO Modulation in AD
Enrolling by invitationNCT07191821
Start: 2025-08-08End: 2027-06-01Target: 51Updated: 2025-10-01
Role of a Mitochondrial Receptor in Blood Sugar Regulation
RecruitingNCT07682233
Start: 2026-03-27End: 2028-09-01Target: 50Updated: 2026-07-02
Unknown Phase
Reproducibility of the 11C-PBR28 PET Signal
WithdrawnNCT02086240
Start: 2014-03-31End: 2018-05-31Updated: 2019-06-10
Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
RecruitingNCT03850301
Start: 2018-01-01End: 2025-01-31Target: 44Updated: 2024-10-15
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
Not yet recruitingNCT06035861
Start: 2026-08-01End: 2026-10-31Target: 6Updated: 2026-03-25
Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease
RecruitingNCT06643013
Start: 2024-10-31End: 2028-04-30Target: 106Updated: 2024-10-15
TSPO Occupancy in the Human Lung
Enrolling by invitationNCT07362290
Start: 2025-09-19End: 2027-03-31Target: 16Updated: 2026-06-01